Pages that link to "Q73932761"
Jump to navigation
Jump to search
The following pages link to Treatment of multiple myeloma (Q73932761):
Displaying 50 items.
- Pegylated liposomal doxorubicin for multiple myeloma (Q24235186) (← links)
- Problems monitoring response in multiple myeloma (Q24676888) (← links)
- Deep Response in Multiple Myeloma: A Critical Review (Q26771228) (← links)
- Endothelial progenitor cells display clonal restriction in multiple myeloma. (Q33247497) (← links)
- Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial (Q33364465) (← links)
- Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma (Q33368609) (← links)
- Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma (Q33376711) (← links)
- Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response (Q33381644) (← links)
- Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China (Q33391566) (← links)
- Bortezomib: the evidence of its clinical impact in multiple myeloma. (Q33400724) (← links)
- Trends in the incidence and survival of multiple myeloma in South East England 1985-2004 (Q33535489) (← links)
- Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection (Q33614395) (← links)
- Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia (Q33731691) (← links)
- Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival (Q33831838) (← links)
- Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. (Q33906748) (← links)
- The best of both worlds - managing the cancer, saving the bone (Q33920055) (← links)
- Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4 (Q34020937) (← links)
- Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. (Q34345502) (← links)
- Cytogenetic manifestations of multiple myeloma heterogeneity (Q34360608) (← links)
- The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing (Q34361282) (← links)
- NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses (Q34388367) (← links)
- The molecular classification of multiple myeloma (Q34530992) (← links)
- Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation (Q34665449) (← links)
- Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. (Q35055386) (← links)
- The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype (Q35070420) (← links)
- Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. (Q35200765) (← links)
- GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis (Q35212312) (← links)
- High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma (Q35263009) (← links)
- Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells (Q35613477) (← links)
- Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies (Q35741937) (← links)
- An update of novel therapeutic approaches for multiple myeloma (Q35759368) (← links)
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla (Q35848978) (← links)
- Autologous stem cell transplantation in hematological malignancies (Q35916382) (← links)
- Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs (Q36085634) (← links)
- Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan (Q36384780) (← links)
- Multiple myeloma in the marrow: pathogenesis and treatments. (Q36725401) (← links)
- Medical management update: multiple myeloma. (Q36732875) (← links)
- Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells (Q36782357) (← links)
- High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients (Q36838506) (← links)
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. (Q36848183) (← links)
- VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma (Q36878944) (← links)
- IRF4 addiction in multiple myeloma (Q36891060) (← links)
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 (Q36910280) (← links)
- Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity (Q36925154) (← links)
- Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth (Q36955402) (← links)
- Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma (Q36975064) (← links)
- The Arkansas approach to therapy of patients with multiple myeloma (Q37028586) (← links)
- Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. (Q37073598) (← links)
- Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma (Q37137940) (← links)
- Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells (Q37161467) (← links)